Optibiotix Health Share Discussion Threads

[deeppockets] 24/10/2017 07:46

When do we expect to see a product on the shelves in UK for LP-LDL?

[elrico] 24/10/2017 07:36

It seems to me that SOH is being ultra conservative here - he appears to have bracketed Galenicum in the same "national" type deals where he expects c10 national type deals where each generate £300-500k pa (£3-6m pa). Galenicum has a much bigger reach than Bened, PharmaBiota and HLH, which SOH also places in the £300-500k pa revenue bracket until a market presence has been built up.

[parob] 24/10/2017 07:24

Link to Galenicum's current STOP&GO range:

[parob] 24/10/2017 07:14

Excellent news. We really are going global with South America and the Middle East added to the list.With each and every deal:- the value of the strain increases- credibility of the science builds- awareness of the brand amongst both consumers and potential partners increases- consumer acceptance of the product builds- we take a step closer to a deal with a large consumer health business- revenues cumulatively build and we move closer to the inflection point and profitability

[judijudi] 24/10/2017 07:12

One of the smaller deals in the pipeline I reckon
But one that’s most welcome

[deeppockets] 24/10/2017 07:08

It also gives possible short term revenue estimates, unusual!

[owenmo] 24/10/2017 07:06

Surely an share price boost trigger.

[primal123] 24/10/2017 07:04

As predicted RNS Tuesday:OptiBiotix Health PLC LPLDL® supply agreement with Galenicum

[mouse20] 24/10/2017 05:52

Telegraph article extract

Doctors put patients off statins

Prescriptions drop for those most at risk of heart attack and stroke as research suggests GPs ignore NHS drive
By Henry Bodkin
PATIENTS most at risk of heart attacks and strokes are still not being prescribed statins despite a drive by the NHS to put more people on the drugs, a study reveals today.
Analysis of nearly 250 GP practices shows that despite the advice to doctors to put millions more people on statins, the proportion of those with the worst outlook taking the cholesterol-lowering drugs has dropped.
In 2014, watchdogs dramatically lowered the threshold for prescribing statins, effectively encouraging doctors to make them available to more patients.
But the latest research suggests patients and GPs have been deterred from following the guidance amid continuing controversy over the drugs.
Last night, experts said that in the privacy of the consulting room, family doctors often pointed out to a patient that they may gain only a small benefit.
“We talk to patients about the risks and benefits on an individual basis,” said Dr Sammuel Finnikin, a GP and Birmingham University academic who led the research. “The majority of ­patients who take statins get no benefit – they think about the side-effects and make their decision.”
‘The majority of ­patients who take statins get no benefit – they think about the side-effects and make their decision’
The study also indicated just one in four patients given statins had been subjected to the proper test.
Critics of statins question their effectiveness and point out that any benefit can be outweighed by side effects that include aching joints, dizziness and nausea. However, statins reduce death from heart disease by around 28 per cent, according to a study published in Circulation last month, while a Lancet report last year found fears of side-
effects to be exaggerated.
It found that if 10,000 patients were treated with the drug for more than five years, only 200, or 2 per cent, would experience negative side-effects.
The latest study, published in the British Journal of General Practice, found that since the National Institute of Health and Care Excellence (Nice) halved the risk threshold in 2014, the rate of prescriptions to those at high risk decreased, but it increased among those at lesser risk.

Lpldl works best for those at the highest risk

[marnewton] 23/10/2017 23:26

Interesting article about statins on the front page of the Telegraph - I say 'interesting', but I haven't read it - the article was featured on the BBC News newspaper review.

M

[parob] 23/10/2017 21:39

Per on twitter just now:

Off to CPHI in Frankfurt on the morning flight tomorrow to meet partners and client. Not least exploring new opportunities.....

[monkeywench1] 23/10/2017 20:05

Hey rampers...dont forget there never were 39 rns.

[marnewton] 23/10/2017 17:58

Always, Parob;¬)

M

[parob] 23/10/2017 17:52

Mar,Are we looking good for a golden cross then? Cheers

[parob] 23/10/2017 17:49

Millennials turning to probiotics more than prior generations

By Erika Kincaid • Oct. 19, 2017

[marnewton] 23/10/2017 17:34

Bounced off the 50 day SMA again...averages pinching tighter;¬)

M

[elrico] 23/10/2017 16:56

I'll be happy if OPTI hold fire for another 4-6 weeks :O)

[primal123] 23/10/2017 16:55

Definitely ODR, us LTH have been waiting patiently while some trade! I definitely believe this time we will move out of the range, it doesn't take much to move this now and hopefully we will hear something soon!

[onedayrodders] 23/10/2017 16:42

I'll be happy to sacrifice 39 RNS's for just 1 providing the content is enough to move us up finally out of this trading range.

:O)

[primal123] 23/10/2017 16:12

Looks like a blue finish!! :-)

[judijudi] 23/10/2017 15:29

Very sanguine
:)

[1bokke] 23/10/2017 15:18

F3rdinand ref post 28264I agree completely on the share price however with regards to the 14th August point I would only say that since then we have had the following announcements of note:22 Aug - Manufacturing and supply agreement with Sacco.5 Sept - Scale up and manufacturing agreement with Tata.13 Sept - Strategic partnership with Bened.19 Sept - Intention to launch improved Slimbiome supplement. 27/28 Sept - launch of Lp(ldl) and Slimbiome in the US.It might not be 39 Rns yet but we still have November and early December to go.. Don't forget with Optis model we are reliant on these companies to go and get the sales and it will take time to build and convert a sales pipeline into closed orders that generate revenues.